

Q3 FY25E Life Insurance Earnings Preview



Result Preview

07th January 2025

MARKET DATA

Page 2

Life Insurance

Margins bottomed out; Expect sequential improvement in Q3FY25E

COVERAGE STOCKS

Coverage	СМР	Target (INR)	Upside	Recom.		Close	1M (%)	YTD (%)
					Nifty	23,616	-4.3%	-0.1%
HDFC Life Insurance Company Ltd	606	845	39.5%	BUY	Sensex	77,965	-4.6%	0.0%
ICICI Prudential Life Insurance Company Ltd 66	662	662 750	13.3%	HOLD	Nifty Fin. Services	23,341	-5.6%	-1.3%
					USD / INR	85.8	1.4%	-0.2%
SBI Life Insurance Company Ltd	1,435	1,901	32.5%	BUY				

Note: TP and recommendation have been retained from previous update reports; we will review it post detailed Q3FY25E results analysis and conference call of the said companies. Source: Bloomberg, NSE; Data as of January 06, 2025

SECTOR OVERVIEW

- In Q3FY25E, the business growth is expected to remain steady, with life insurers under our coverage universe likely to report an 18.4% YoY increase in APE, aided by strong demand for ULIPs and improved traction in the protection segment despite regulatory changes regarding surrender value. In Q3FY25E, we expect the aross premium for life insurers under our coverage to grow by 15.5% YoY.
- > Expanding distribution networks and digital channels in smaller towns and rural areas are tapping into previously underpenetrated markets, contributing significantly to premium growth.
- > Introducing customized and hybrid products catering to varied customer needs, such as unit-linked plans, savings products, and term plans, is attracting a broader customer base.
- > Growth in group insurance policies, particularly from corporates focusing on employee benefits, is expected to boost overall premium collections, especially for HDFCLIFE significantly.
- > The bancassurance channel will continue to remain a healthy contributor to premium growth during the quarter for HDFCLIFE and SBILIFE, complemented by cross-selling efforts through NBFCs and digital partners. However, the industry will continue to see improving performance from their agent network, aiding in improving penetration, especially in underserved areas, aiming to provide greater access to insurance products across diverse demographics.
- The non-par segment is expected to see a gradual improvement in its contribution, complemented by continued momentum in the Annuity and Protection segments, fueled by an expanding product portfolio and widening geographical reach.
- > For our coverage, VNB growth is expected at 14.9% YoY, driven by product mix optimization, and non-par repricing. VNB margins will see minor improvement with stability in the product mix despite higher expenses and regulatory changes.
- > Persistency ratios are expected to improve by ~50-75 bps YoY across the companies we cover, with consistency in maintaining retention rates. Solvency ratios will continue to remain robust across the sector.

Page 3

Life Insurance

Valuation:

- The Indian life insurance sector is poised for steady growth in FY26E, supported by rising premium collections, proactive regulatory measures, an increased push towards protection products, enhanced distribution capabilities, product innovation, and improving macroeconomic indicators.
- Continued investments in digital platforms for sales and service delivery are enhancing operational efficiencies and customer experience. Increased focus on Tier-2 and Tier-3 markets, aided by digital channels and partnerships, is unlocking growth potential in underpenetrated regions.
- The growing middle class, increasing awareness of insurance, and regulatory tailwinds provide a long-term growth runway for the sector.
- Insurers are effectively navigating new surrender value regulations and recalibrating distribution strategies, mitigating potential adverse impacts.
- Key parameters to monitor this quarter include: 1) the business outlook for FY26E, 2) anticipated performance in high-margin segments, 3) VNB margin projections for FY26E, and 4) any adjustments in pricing strategies.
- For FY26E, the average P/EV of the listed companies under our coverage is 1.9x, which is still lower than the industry's historical average of 2.8x.
- We remain positive on HDFC Life due to its strong brand recognition, diversified product portfolio, and enhanced business strategies. Similarly, SBI Life stands out for its robust long-term growth prospects and healthy balance sheet strength.



Source: NSE

Life Insurance

Exhibit 1: Quarterly result expectation for companies under coverage

Q3FY25E (INR in Mn) HDFCLIFE	Outperform	Base	Underperform	View
Gross Written Premium (GWP)	186,877	181,434	175,991	 We expect a 16.9% YoY (+7.2% QoQ) growth in GWP. The growth will be driven by ~18.0% YoY growth in renewal premiums.
Annualized Premium Equivalent (APE)	40,273	39,100	37,927	• We see the new business premium segment grow by 12.2% YoY, led by a 28.0% growth in the First-year premium segment. Thus, the premium growth is expected to reflect an APE growth of 22.5% YoY/ 1.5% QoQ in the
Value of New Business (VNB)	10,068	9,697	9,103	base case scenario, with a possibility of a +/- 3% deviation.
VNB Margins	25.0%	24.8%	24.0%	 In the base scenario, VNB margins are expected to be around 24.8%, an improvement of 51 bps QoQ led by a high- yielding product mix.
AUM (INR in Bn)	3,515	3,412	3,310	• We expect margins to remain stable at 24.0% in the underperforming scenario.
IPRU				
Gross Written Premium (GWP)	127,232	121,174	115,115	 In the base case, we expect GWP for IPRU to grow by 17.8% YoY (+8.4% QoQ), led by 29.1% YoY growth in New Business
Annualized Premium Equivalent (APE)	26,713	25,441	24,169	Premiums. The group business will continue to see strong momentum.
Value of New Business (VNB)	6,411	5,979	5,317	 In the base case scenario, APE is likely to grow by 33.4% YoY (+1.6% QoQ), with a possibility of a +/-5.0% deviation. The growth will be led by a 45.0% YoY growth in the
VNB Margins	24.0%	23.5%	22.0%	First-Year premium segment.
AUM (INR in Bn)	3,367	3,301	3,235	 IPRU is expected to see margins at 23.5%, an improvement of 10 bps QoQ with a slight improvement in the product mix
SBILIFE				
Gross Written Premium (GWP)	267,525	254,786	242,047	 In the base case, we expect GWP to grow by 13.4% YoY (+24.8% QoQ), driven by 20.0% growth in renewal premiums.
Annualized Premium Equivalent (APE)	71,876	68,453	65,031	 We anticipate APE to grow by 11.7% YoY/ 27.0% QoQ, led by 15.3% growth in the new business premium segment.
Value of New Business (VNB)	19,766	18,482	17,233	 We expect VNB margins to see a contraction of 41 bps YoY but an improvement of 10 bps QoQ at 27.0% in a base-case scenario.
VNB Margins	27.5%	27.0%	26.5%	 In an underperforming scenario, we expect VNB margins to be around 27.5%, while an
AUM (INR in Bn)	4,612	4,521	4,431	expansion of 60 bps QoQ in an outperformance scenario.

Q3FY25 Earning Preview

II 07th January 2025

DEVEN CHOKSEY RESEARCH

Page 5

Life Insurance



Source: NSE, Bloomberg

Q3FY25 Earning Preview

II 07th January 2025

Page 6

Life Insurance

Rating Legend (Expected over a 12-month period)					
Our Rating	Upside				
Buy	More than 15%				
Accumulate	5% – 15%				
Hold	0 – 5%				
Reduce	-5% – 0				
Sell	Less than – 5%				

ANALYST CERTIFICATION:

I, Karan Kamdar (CA), Research Analyst, author and the name subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect my views about the subject issuer(s) or securities. I also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

Terms & Conditions and other disclosures:

DRChoksey FinServ Private Limited (hereinafter referred to as DCFPL) is a registered member of SEBI as a Research Entity vides Registration No. INH000011246 under SEBI (Research Analyst) Regulations, 2014, Portfolio Managers Entity vides Registration No. INP000007906 under SEBI (PORTFOLIO MANAGERS) Regulations, 2020 & Investment Adviser Entity vides Registration No. INA000017903 under SEBI (INVESTMENT ADVISERS) REGULATIONS, 2013.

The information and opinions in this report have been prepared by DCFPL and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of DCFPL. While we would endeavor to update the information herein on a reasonable basis, DCFPL is not under any obligation to update the information. Also, there may be regulatory, compliance or other reasons that may prevent DCFPL from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or DCFPL policies, in circumstances where DCFPL might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. DCPFL will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment trisks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. DCPFL accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. Our employees in sales and marketing team, dealers and other any or all of the foregoing, among other things, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

We submit that no material disciplinary action has been taken on DCFPL and its associates (Group Companies) by any Regulatory Authority impacting Equity Research Analysis activities.

DCFPL prohibits its associate, analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analyst covers.

DCFPL or its associates (Group Companies) collectively or its research analyst, or relatives do not hold any financial interest/beneficial ownership of more than 1% (at the end of the month immediately preceding the date of publication of the research report) in the company covered by Analyst, and has not been engaged in market making activity of the company covered by research analyst.

It is confirmed that, I, Karan Kamdar Research Analyst of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months. Compensation of our Research Analysts is not based on any specific brokerage service transactions.

DCFPL or its Associates (Group Companies) have not managed or co-managed public offering of securities for the subject company in the past twelve months.

DCFPL or its associates (Group Companies) collectively or its research analyst, or relatives might have received any commission/compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of brokerage services or specific transaction or for products and services other than brokerage services.

DCFPL or its associates (Group Companies) collectively or its research analyst, or relatives might have received any commission/compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report other than investment banking or merchant banking or brokerage services from the subject company

DCFPL encourages the practice of giving independent opinion in research report preparation by the analyst and thus strives to minimize the conflict in preparation of research report. DCFPL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither DCFPL nor Research Analysts his associate or his relative, have any material conflict of interest at the time of publication of this report.

It is confirmed that, Karan Kamdar, Research Analyst do not serve as an officer, director or employee of the companies mentioned in the report.

DCFPL or its associates (Group Companies) or its research analyst has may been engaged in market making activity for the subject company.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other Jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject DCFPL and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform them of and to observe such restriction.

The securities quoted are for illustration only and are not recommendatory

Please send your feedback to researchdesk@devenchoksey.com

DRChoksey FinServ Private Limited

CIN Number - U67100MH2020PTC352816

Registered Office and Corporate Office:

5th Floor Abhishek Building, Behind Monginis Cake Factory, Off New Link Road, Andheri West, Mumbai-400058